Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis  M. De Vos, O. Dewit, G. D'Haens,

Published byGustaaf Mertens Modified over 5 years ago

Similar presentations

Presentation on theme: "Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis  M. De Vos, O. Dewit, G. D'Haens,"— Presentation transcript:

1 Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis  M. De Vos, O. Dewit, G. D'Haens, F. Baert, F. Fontaine, S. Vermeire, D. Franchimont, T. Moreels, D. Staessen, L. Terriere, B. Vander Cruyssen, E. Louis  Journal of Crohn's and Colitis  Volume 6, Issue 5, Pages (June 2012) DOI: /j.crohns Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

2 Figure 1 Evolution of calprotectin levels under infliximab therapy in function of the induction of endoscopic remission at week 10. Legend: Boxplots describe medians and interquartile ranges of the completers Lines show the result of the mixed models analysis (ITT analysis). Journal of Crohn's and Colitis 2012 6, DOI: ( /j.crohns ) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

3 Figure 2 Evolution of calprotectin levels under infliximab therapy in function of the induction of endoscopic remission at week 10 and concomitant use of corticosteroids. Legend: Boxplots describe medians and interquartile ranges of the completers. Lines show the result of the mixed models analysis (ITT analysis). Journal of Crohn's and Colitis 2012 6, DOI: ( /j.crohns ) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

Download ppt "Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis  M. De Vos, O. Dewit, G. D'Haens,"

Similar presentations

High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,

High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
How do psychological variables influence coping strategies in inflammatory bowel disease?  Marta Iglesias-Rey, Manuel Barreiro-de Acosta, Francisco Caamaño-Isorna,

How do psychological variables influence coping strategies in inflammatory bowel disease?  Marta Iglesias-Rey, Manuel Barreiro-de Acosta, Francisco Caamaño-Isorna,
Serta Kılınçalp, Akif Altınbaş, Ömer Başar, Murat Deveci, Osman Yüksel 

Serta Kılınçalp, Akif Altınbaş, Ömer Başar, Murat Deveci, Osman Yüksel 
Does the endoscopic appearance of the ileocecal valve suggest the severity of Crohn's disease in the terminal ileum?  Tamás Molnár, Klaudia Farkas, Ferenc.

Does the endoscopic appearance of the ileocecal valve suggest the severity of Crohn's disease in the terminal ileum?  Tamás Molnár, Klaudia Farkas, Ferenc.
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease  Giammarco Mocci, Manuela Marzo, Alfredo Papa, Alessandro.

Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease  Giammarco Mocci, Manuela Marzo, Alfredo Papa, Alessandro.
Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years 

Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years 
Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease—what is the role of anti-TNF antibody? 

Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease—what is the role of anti-TNF antibody? 
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 
YouTube® and inflammatory bowel disease

YouTube® and inflammatory bowel disease
A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis  Urpo Kinnunen,

A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis  Urpo Kinnunen,
Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?  Christian Jakobsen, Vibeke Wewer, Frederikke Urne,

Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?  Christian Jakobsen, Vibeke Wewer, Frederikke Urne,
Liver abscess of the caudate lobe due to Staphylococcus aureus in an ulcerative colitis patient: First case report  Andreia Albuquerque, Fernando Magro,

Liver abscess of the caudate lobe due to Staphylococcus aureus in an ulcerative colitis patient: First case report  Andreia Albuquerque, Fernando Magro,
Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years 

Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years 
Ineffectiveness of infliximab therapy in severe infantile Crohn's disease  Nuray Uslu, Yusuf Usta, Inci Nur Saltik-Temizel, Hulya Demir, Figen Gürakan,

Ineffectiveness of infliximab therapy in severe infantile Crohn's disease  Nuray Uslu, Yusuf Usta, Inci Nur Saltik-Temizel, Hulya Demir, Figen Gürakan,
Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: The first case in the literature  Gurhan.

Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: The first case in the literature  Gurhan.
Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis  Vincent Billioud, Alexander C. Ford,

Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis  Vincent Billioud, Alexander C. Ford,
High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,

High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD)  Mariam Aguas, Vicente Garrigues,

Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD)  Mariam Aguas, Vicente Garrigues,
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 
Microscopic colitis patients have increased proportions of Ki67+ proliferating and CD45RO+ active/memory CD8+ and CD4+8+ mucosal T cells  Ashok Kumar.

Microscopic colitis patients have increased proportions of Ki67+ proliferating and CD45RO+ active/memory CD8+ and CD4+8+ mucosal T cells  Ashok Kumar.

Similar presentations

Ads by Google